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significantly lower CSF levels of the methyl group donor SAM 
(193  8 31 vs. 207  8 37 nmol/l; p = 0.032). Accordingly, the 
SAM/SAH ratio, which represents the methylation capacity, 
was significantly lower in the CSF of the AD patients (7.6  8 
2.4 vs. 9.1  8 2.8; p = 0.003). Further, explorative analysis of 
all subjects showed that CSF SAM levels were lower in carri-
ers of the APOE4 allele compared with noncarriers (189  8 30 
vs. 207  8 36 nmol/l; p = 0.010). Of the individuals with CSF 
SAM levels in the lowest quartile, 63% carried the APOE4 al-
lele compared with 17% of the individuals with CSF SAM lev-
els in the highest quartile (Pearson:   2 = 9.9; p = 0.002; odds 
ratio 0.126, 95% confidence interval 0.32–0.49).  Conclusion: 
These data suggest that AD is associated with lower CSF SAM 
levels and that this is at least partly due to an association of 
the APOE4 allele with reduced SAM levels in the CSF. 
 Copyright © 2010 S. Karger AG, Basel 
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 Abstract 
 Background: Increased plasma homocysteine levels have 
been described as an independent risk factor for Alzheimer’s 
disease (AD), but the underlying pathophysiology is unclear. 
 Objective: This single-center, cross-sectional, correlational 
study analyzed homocysteine metabolism in 60 AD patients 
and 60 control subjects.  Methods: Fasting plasma levels of 
vitamin B 12 , folate and homocysteine as well as cerebrospi-
nal fluid (CSF) levels of folate derivates,  S -adenosylmethio-
nine (SAM),  S -adenosylhomocysteine (SAH) and homocyste-
ine were measured. In addition, the apolipoprotein E (APOE) 
genotype was determined.  Results: As expected, the APOE4 
allele was significantly overrepresented in AD patients com-
pared with controls (p  ! 0.001). Homocysteine plasma levels 
in the highest quartile were more frequent in the AD patients 
than in the controls (p = 0.008). In addition, AD patients had 
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 Introduction 
 Sporadic Alzheimer’s disease (AD) is the most com-
mon cause of dementia in the elderly. Known risk factors 
for AD include age, gender, the presence of the apolipo-
protein E 4 (APOE4) allele and increased homocysteine 
plasma levels  [1, 2] . Hyperhomocysteinemia, often related 
to folate or vitamin B 12 deficiency, is a common finding 
in the elderly  [3] and is associated with cognitive impair-
ment and cognitive decline  [4, 5] . The association be-
tween hyperhomocysteinemia and AD is well established; 
however, the underlying pathophysiology remains unex-
plained. In particular, it is not known whether the homo-
cysteine level itself or other components of the homocys-
teine metabolism play a role in the development of AD. 
Recent studies in cell culture experiments and mouse 
models suggested that 2 metabolites of homocysteine,  S-
 adenosylmethionine (SAM) and  S- adenosylhomocyste-
ine (SAH), may be important in Alzheimer pathogenesis, 
e.g. by influencing expression of presenilin 1 and   -
secretase, leading to an increase in A  production  [6–8] . 
SAM serves as a ubiquitous methyl group donor and is 
necessary, for example, for the synthesis of neurotrans-
mitters, neuronal membrane stability and DNA methyla-
tion  [9, 10] . After transmethylation, the resulting degra-
dation product of SAM is SAH, which is hydrolyzed to 
homocysteine ( fig. 1 ).
 A few studies have investigated the association be-
tween parameters of homocysteine metabolism in the ce-
rebrospinal fluid (CSF) of patients and AD. The compar-
ison of CSF of 8 AD patients and 6 control subjects re-
vealed higher CSF homocysteine levels in the AD group 
 [11] . In contrast, another study investigating CSF of 83 
control subjects and 38 AD patients found that homocys-
teine levels increased with age but were not associated 
with AD  [12] . With regard to SAM and SAH, Mulder et 
al.  [13] investigated the CSF of 30 AD patients and 28 con-
trols and did not observe any significant differences in 
these parameters between the 2 groups studied. However, 
this study may have been limited by the fact that 20 of the 
controls also presented ‘subjective memory complaints’, 
but did not have a diagnosis of AD. Another study re-
ported lower CSF SAM levels in 9 patients with AD com-
pared with 29 neurological disease control subjects  [14] .
 In the present study, we compared the fasting CSF lev-
els of SAM, SAH, homocysteine and folate fractions as 
well as fasting plasma levels of folate, vitamin B 12 and ho-
mocysteine in 60 AD patients with those in 60 controls 
without cognitive impairment to further investigate the 
association of the homocysteine metabolism with AD.
 Subjects and Methods 
 The 60 Caucasian study participants with AD were referred to 
the Memory Clinic, Department of Psychiatry, University of 
Bonn, for investigation of their cognitive complaints. They met 
clinical diagnostic criteria for probable AD according to the Na-
tional Institute of Neurological and Communicative Disorders 
and Stroke and Related Disorders Association  [15] and DSM-IV 

















 Fig. 1. Homocysteine metabolism. The 
sulfur-containing amino acid methionine 
is activated to SAM, which is a ubiquitous 
methyl group donor. The degradation 
product of SAM is SAH, which is hydro-
lyzed to homocysteine. Homocysteine can 
be remeth ylated to methionine and SAM, 
which depends on derivates of folate (5,10-
MTHF, 5-MTHF) and vitamin B 12 as co-
factors. Alternatively, homocysteine can 
be transsulfurated to cysteine as a compo-
nent of glutathione, which depends on vi-
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 Diagnosis of AD was based on neuropsychological and clini-
cal evaluation, including the Mini-Mental State Examination 
(MMSE), and was approved by a consensus conference of psychi-
atrists and neuropsychologists prior to the metabolite measure-
ments. The presence of relevant vascular cerebral damage was
excluded for all study participants with AD by computed tomog-
raphy or magnetic resonance tomography and the Hachinsky 
Ischemic Score (score  ! 4)  [16] . Blood and CSF samples from all 
patients were obtained at the diagnostic workup at which the di-
agnosis of AD was first made; thus, the age of the patients at the 
time that the samples were collected was the same as the age at 
diagnosis.
 As disease controls, we recruited 60 consecutive Caucasian pa-
tients who underwent lumbar puncture at the Department of 
Neurology, University of Bonn, for different indications such as 
exclusion of central nervous system inflammation, exclusion of 
aneurysmal subarachnoid hemorrhage or exclusion of meningi-
tis. All controls were assessed with the MMSE. Exclusion criteria 
included age under 18 years, history or evidence of cognitive de-
cline as assessed with the MMSE  [17] , subjective mental disorders, 
regular intake of vitamin supplements, neurodegenerative or in-
flammatory diseases of the central nervous system and other se-
vere or unstable illnesses such as symptomatic cardiac disease, 
renal or hepatic dysfunction, insulin-dependent diabetes melli-
tus, untreated thyroidal dysfunction or excessive alcohol intake. 
In addition, CSF samples indicating blood-CSF barrier distur-
bances or inflammatory signs, defined as CSF whole protein con-
tent  1 500 mg/dl and more than 5 leukocytes/mm 3 , were excluded 
from both the AD group and controls. Diagnostic lumbar punc-
tures were performed at the Departments of Neurology or Psy-
chiatry, University of Bonn. Lumbar puncture belonged to the 
diagnostic workup within the clinical routine in all cases of de-
mentia and was not primarily done for study purposes. A stan-
dardized technique with a 20-gauge ‘atraumatic’ spinal needle 
and the patient in a sitting or lying position was applied. CSF 
samples were immediately put on dry ice and then stored at –80  °  C 
until assayed. Fasting plasma homocysteine concentrations were 
measured by means of particle-enhanced immunonephelometry 
with a BN II System (Siemens Healthcare Diagnostics, Eschborn, 
Germany). Fasting serum vitamin B 12 and folate concentrations 
were measured by means of a competitive chemiluminescent im-
munoassay with an Access TM Immunoassay System (Beckman 
Coulter, Krefeld, Germany). Deproteinized serum samples for the 
analysis of SAM and SAH were not available. CSF was analyzed 
by tandem mass spectrometry for folate derivates [5-methyltetra-
hydrofolate (5-MTHF), 5,10-methylenetetrahydrofolate (5,10-
MTHF), tetrahydrofolate (THF), 5-formyl-THF, folic acid], SAM, 
SAH and homocysteine as described previously  [18, 19] . Homo-
cysteine was measured in CSF by HPLC using fluorescence detec-
tion as previously described  [20] . Leukocyte genomic DNA was 
isolated with the Qiagen blood isolation kit (Qiagen, Hilden, Ger-
many). The APOE genotype was determined as previously de-
scribed  [21] .
 For statistical analysis, univariate analysis of variance (ANO-
VA) was used to compare CSF and blood parameters between AD 
patients and controls. CSF SAM levels in APOE4 carriers and 
APOE4 noncarriers were compared by an independent-samples t 
test. As age and gender differed significantly between patients and 
controls, the results obtained from ANOVA analysis were retested 
by multivariate nominal regression analysis with age and gender 
as covariables for adjustment of differences. Due to unknown in-
teractions between the blood and the CSF parameters, the multi-
variate analysis was performed separately for blood and CSF pa-
rameters. The association of the APOE4 allele with AD diagnosis 
was analyzed with Pearson’s   2 test. Alpha was set as two-sided 
0.05. Plasma and CSF levels of homocysteine were compared by 
Pearson’s bivariate analysis of correlation. The study was ap-
proved by the local ethics committee. Written informed consent 
was obtained from all study participants or their trustees.
 Results 
 We compared samples from 60 AD patients (mean age 
at diagnosis  8 standard deviation: 73  8 8 years; 43 
women) with samples from 60 controls (62  8 10 years; 
24 women). The mean MMSE score of controls was 29.0 
(95% confidence interval 28.3–29.7) in comparison to 
21.5 (20.5–22.5) in the AD patients (ANOVA: F = 152;
p  ! 0.001). As expected, the APOE4 allele was signifi-
cantly overrepresented in AD patients compared with 
controls (87 vs. 27% carriers; Pearson’s   2 test:   2 = 38.0; 
p  ! 0.001). We did not observe significant differences be-
tween AD patients and controls with regard to mean plas-
ma levels of homocysteine, vitamin B 12 , total folate or cre-
atinine ( table 1 ).
 In the CSF, 5-MTHF was present at concentrations 
higher than the quantification limit in all samples; 5,10-
MTHF was detectable in 18 samples, and formyl-THF 
and THF were detectable in fewer than 10 samples. Folic 
acid, the synthetic form used for folate supplementations, 
was not detectable in any of the samples. The quantifica-
tion limit for the cumulative group of the folate fractions 
was approximately 0.4 nmol/l. There was no difference in 
CSF levels of 5-MTHF (F = 0.54; p = 0.464), 5,10-MTHF 
(F = 1.54; p = 0.218), formyl-THF (F = 0.31; p = 0.580) and 
THF (F = 0.05; p = 0.818) between AD patients and con-
trols. Because of the limited number of data, the odds 
ratio of quartiles was not calculated for CSF folate frac-
tions.
 Whereas there was no significant difference in CSF or 
plasma homocysteine levels between AD patients and 
controls, the frequency of homocysteine plasma levels in 
the highest quartile was significantly higher in the AD 
patients than in the controls (p = 0.008;  table 1 ). Accord-
ingly, homocysteine plasma levels in the highest quartile 
were associated with AD in multivariate nominal regres-
sion analysis with age and gender as covariables and with 
a diagnosis of AD versus control as the dependent vari-
able (p = 0.023). AD patients showed significantly lower 
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higher CSF levels of SAH (ANOVA: p = 0.037). Accord-
ingly, the SAM/SAH ratio was significantly lower in the 
AD patients (p = 0.003). When we retested these results 
in multivariate regression analysis with age and gender as 
a covariables, the difference in SAM between AD patients 
and controls was confirmed (Wald = 3.81; p = 0.048), 
whereas the difference in SAH was not (Wald = 0.022;
p = 0.961).
 As the APOE genotype is a major risk factor for AD, 
we next tested whether the observed associations be-
tween metabolites and AD were independent of the 
APOE genotype. When the APOE genotype was added as 
a covariable to the multivariate model, regression analy-
sis showed no association between AD and SAM levels 
(Wald = 0.460; p = 0.543). Thus, we suspected that CSF 
levels of SAM were associated with the APOE genotype, 
and we additionally tested metabolite levels in strata of 
the APOE genotype. While the other parameters showed 
no significant differences, CSF SAM levels were signifi-
cantly lower in the carriers of the APOE4 allele (ANOVA: 
F = 6.93, p = 0.010, for AD patients plus controls). This 
association was significant when patients and controls 
were analyzed together ( table 2 ), but not when patients 
and controls were analyzed separately. Of the individuals 
with CSF SAM levels in the lowest quartile, 63% carried 
the APOE4 allele compared with 17% of the individuals 
with CSF SAM levels in the highest quartile (Pearson:
  2 = 9.9; p = 0.002; odds ratio 0.126, 95% confidence in-
terval 0.32–0.49).
 In a generalized linear model, there was no significant 
interaction between AD diagnosis and the APOE4 allele 
with regard to SAM levels (not shown). SAM levels did 
not correlate with the MMSE score in the AD patients.
 Discussion 
 In the present study, several parameters of homocys-
teine metabolism were analyzed in the CSF and plasma 
of 60 AD patients and 60 control subjects without cogni-
tive impairment. Due to differences in age and gender 
between patients and controls as a limitation, we per-
formed multivariate analysis with age and gender as
covariables in addition to univariate analyses. Whereas 
homocysteine plasma levels were not significantly associ-
ated with AD in ANOVA, individuals with homocysteine 
Table 2.  CSF levels of SAM (nmol/l) according to the APOE4 genotype
APOE4 present APOE4 absent t test
All subjects (n = 120) 189830 (n = 50) 207836 (n = 70) t = 2.63; p = 0.010
AD patients (n = 60) 188829 (n = 43) 199836 (n = 17) t = 1.10; p = 0.240
Controls (n = 60) 198834 (n = 7) 210836 (n = 53) t = 0.72; p = 0.474
Table 1.  Blood and CSF parameters in AD patients and controls
Parameter AD patients (n = 60) Controls (n = 60) ANOVA OR quartiles
Homocysteine (plasma), mol/l 14.184.3 (12.9–15.3) 12.785.4 (11.3–14.1) F = 2.20; p = 0.144 4.889 (1.513–15.793); p = 0.008
Vitamin B12 (serum), pmol/l 2728192 (219–323) 2488103 (221–276) F = 0.636; p = 0.427 1.00 (0.350–2.859); p = 0.989
Total folates (serum), nmol/l 15.6287.04 (13.69–17.52) 14.0587.74 (11.99–16.09) F = 1.24; p = 0.269 2.500 (0.828–7.548); p = 0.104
Creatinine (plasma), mol/l 74.3813.3 (69.9–77.9) 89.4877.4 (66.4–111.5) F = 1.73; p = 0.191 0.650 (0.226–1.866); p = 0.423
SAM (CSF), nmol/l 193831 (184–201) 207837 (197–217) F = 4.74; p = 0.032 0.222 (0.072–0.686); p = 0.009
SAH (CSF), nmol/l 26.986.2 (25.2–28.5) 24.386.8 (22.5–26.1) F = 4.44; p = 0.037 3.333 (1.098–10.116); p = 0.034
SAM/SAH (CSF) 7.682.4 (6.9–8.3) 9.182.8 (8.4–9.9) F = 9.92; p = 0.003 0.152 (0.048–0.484); p = 0.001
Homocysteine (CSF), nmol/l 71.9843.5 (59.9–83.9) 77.6852.6 (63.8–91.4) F = 0.39; p = 0.536 0.750 (0.262–2.150); p = 0.592
M ean 8 standard deviation and 95% confidence intervals (in parentheses) are given. Odds ratio (OR) quartiles: Mantel-Haenszel common odds ra-
tio estimates with asymptomatic 95% confidence intervals (in parentheses) and asymptomatic two-sided significance are given for the distribution of the 
highest and lowest quartiles of the respective parameter between AD patients and controls. An odds ratio lower than 1.0 means that the lowest quartile 
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plasma levels in the highest quartile significantly more 
often belonged to the AD group in comparison to indi-
viduals with homocysteine levels in the lowest quartile. 
This is in line with the known association between ele-
vated homocysteine plasma levels and AD  [1] . However, 
we did not observe higher homocysteine CSF levels in AD 
patients as previously reported  [22] .
 In addition, we did not detect significant differences 
in blood levels or quartiles of vitamin B 12 , folate or cre-
atinine, nor in CSF levels or quartiles of folate fractions. 
However, in the AD patients, we observed significantly 
lower CSF levels of SAM and a significantly lower SAM/
SAH ratio. As the observed lower levels of SAM in CSF 
were also significant in a multivariate model, this differ-
ence is unlikely to be explained by differences in age and 
gender between AD patients and controls. This confirms 
a previous report by Bottiglieri et al.  [14] , who observed 
lower CSF levels of SAM in 9 AD patients in comparison 
to 29 patients with other neurological diseases. Accord-
ingly, in a postmortem analysis, the concentration of 
SAM was severely decreased in the brains of AD patients 
 [23] .
 Due to the role of SAM as a ubiquitous methyl group 
donor and SAH as a strong inhibitor of SAM-dependent 
transmethylation reactions, lower levels of SAM and 
higher levels of SAH are supposed to result in a reduced 
methylation capacity  [24] . It was previously suggested 
that low SAM levels are associated with DNA demethyl-
ation followed by increased expression of presenilin 1 and 
  -secretase, leading to an increase in A  production. 
Supplementation of SAM prevented these changes in cell 
culture experiments and mouse models  [6–8] . Addition-
ally, high concentrations of the hyperphosphorylated tau 
protein in CSF, which predict the development of demen-
tia  [25] , were associated with low activity of the SAM-
dependent protein phosphatase PP2A  [26] . Thus, low 
brain or CSF levels of SAM and high levels of the SAM 
inhibitor SAH might promote both A  production and 
accumulation of hyperphosphorylated tau protein. An-
other aspect of a possible association between methio-
nine metabolism and neurodegenerative disorders is oxi-
dative stress. The transsulfuration reaction of homocys-
teine to cysteine, a precursor of glutathione, is activated 
by SAM  [9] . Therefore, a lack of SAM may result in a re-
duced antioxidative capacity and increased oxidative 
stress, a hallmark of several neurodegenerative condi-
tions including AD  [27, 28] . Recent findings showed that 
oral substitution of SAM results in an increase in both 
plasma and CSF levels of SAM, and SAM substitution 
may effect some clinical improvement in AD patients 
 [29] .
 The second interesting observation in our study was 
the association of CSF levels of SAM with the APOE4 al-
lele. Knowing that these results are limited by the small 
sizes of the respective subgroups and by the limitations of 
pooling patients and controls for such analyses, the asso-
ciation of SAM levels with the APOE4 allele was not sig-
nificant in separate analyses of patients and controls, al-
though both (as yet) healthy and demented carriers of the 
APOE4 allele had lower levels of SAM than noncarriers. 
This observation leads to the question whether there is a 
biological effect of APOE on SAM, which remains specu-
lative.
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